Rose Conway-Walsh (Mayo, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

181. To ask the Minister for Finance if the commercial terms under which public investment was made by ISIF in a company (details supplied) assure the State preferential access to genome data collected by the company; if so, the details of preferential access; and if he will make a statement on the matter. [41649/21]

Paschal Donohoe (Dublin Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The NTMA have informed me that in line with its double bottom line mandate, ISIF made an investment in Genuity Science. ISIF’s investment was, amongst other things, aimed at supporting the creation of a precision medicine hub in Ireland which it was hoped would have associated benefits to Ireland. ISIF’s role in its investments is that of an investor/shareholder with the day to day operations of such companies including Genuity typically being managed by the relevant executive management team. Genuity Science is a standalone commercial entity and decisions relating to its commercial activities, including in relation to genetic information it holds, are a matter for Genuity Science.